Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/24/2025

Treatment of Klebsiella pneumoniae Urinary Tract Infections

Introduction to Treatment Options

  • The World Society of Emergency Surgery (WSES) discourages extended use of cephalosporins due to selection pressure resulting in emergence of resistance, particularly in settings with high incidence of ESBL-producing Enterobacteriaceae 1
  • For ESBL-producing strains, carbapenems are generally preferred over piperacillin/tazobactam 2

Treatment of ESBL-Producing K. pneumoniae

  • For suspected ESBL-producing K. pneumoniae, consider carbapenems as first-line therapy (ertapenem, meropenem, imipenem) 2, 5
  • Piperacillin/tazobactam may be considered for non-severe infections if susceptibility is confirmed 2

Treatment of Carbapenem-Resistant K. pneumoniae

  • Ceftazidime/avibactam is recommended for carbapenem-resistant K. pneumoniae 3
  • Aminoglycosides are particularly effective for UTIs due to high urinary concentrations 3, 4
  • Consider polymyxin-based combination therapy if other options are not available 3

General Treatment Principles

  • Treatment should be guided by local epidemiology and susceptibility testing 2
  • De-escalation of therapy based on culture results is recommended to reduce selection pressure for resistance 1
  • Duration of therapy for complicated UTI is generally recommended to be 7-14 days 5